ExCellThera_RGB.png
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
November 29, 2021 08:05 ET | ExCellThera
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera_RGB.png
ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells
July 13, 2021 08:05 ET | ExCellThera
MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...
ExCellThera_RGB.png
Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health
April 21, 2021 08:02 ET | ExCellThera
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells...
ExCellThera_RGB.png
ExCellThera announces UM171 mechanism of action
January 07, 2021 11:15 ET | ExCellThera
MONTRÉAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera_RGB.png
ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy
December 11, 2020 07:55 ET | ExCellThera
MONTREAL, Dec. 11, 2020 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera_RGB.png
ExCellThera announces publication in The Lancet Haematology highlighting excellent clinical results of ECT-001 in patients with haematological malignancies
November 06, 2019 07:00 ET | ExCellThera
MONTREAL, Nov. 06, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use,...
ExCellThera_RGB.png
ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center
May 07, 2019 08:05 ET | ExCellThera
MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera_RGB.png
ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation   
April 23, 2019 08:05 ET | ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera_RGB.png
ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia
March 25, 2019 08:07 ET | ExCellThera
MONTREAL, March 25, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera_RGB.png
ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease
December 17, 2018 08:05 ET | ExCellThera
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced...